Udvalget konkluderede, at fordelene ved Zerit kombineret med andre antiretrovirale midler opvejer risiciene i behandlingen af hiv- inficerede patienter.
The Committee decided that Zerit’ s benefits are greater than its risks in combination with other antiretroviral medicinal products for the treatment of HIV infected patients.